Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 530-541

  García, María J ^a,b   Saucedo Cuevas, Laura Paula ^a   Muñoz Repeto, Iván ^a   Fernández, Victoria ^a   Robles, María J ^e   Domingo, Samuel ^a   Palacios, José ^d   Aracil, Miguel ^c   Nieto, Antonio ^c   Tercero, Juan Carlos ^c   Benítez, Javier ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c PHARMAMAR S A   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NUCLEIC ACID BINDING PROTEIN; PHARMACOLOGICAL BIOMARKER; PROTEIN CUL4A; TRABECTEDIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP G PROTEIN; XRCC3 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; EXCISION REPAIR; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECOMBINATION REPAIR; RETROSPECTIVE STUDY; SARCOMA; UBIQUITINATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CULLIN PROTEINS; DIOXOLES; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; INHIBITORY CONCENTRATION 50; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84876462970     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0768     Document Type: Article

References (43)

1. Fayette J, Coquard IR, Alberti L, Boyle H, Meeus P, Decouvelaere AV, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18:347-53. (Pubitemid 44297245)
2. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107-14.
3. Rinehart KL. Antitumor compounds from tunicates. Med Res Rev 2000;20:1-27. (Pubitemid 30027559)
4. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105. (Pubitemid 32119366)
5. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6. (Pubitemid 32756435)
6. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001;8:1033-49. (Pubitemid 33119181)
7. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007;104: 13062-7. (Pubitemid 351737593)
8. Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008;44:609-18.
9. Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008;7:10-8.
10. Schoffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011;47:1006-12.
11. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-9. (Pubitemid 29272520)
12. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40:17-22.
13. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006;24:3799-808. (Pubitemid 46622318)
14. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9. (Pubitemid 39331153)
15. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 2002;277:41580-9. (Pubitemid 35257462)
16. Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, et al. Sequence-dependent synergistic cytotoxicity of ecteinasci-din-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002;62:6909-15. (Pubitemid 35424080)
17. Aune GJ, Takagi K, Sordet O, Guirouilh-Barbat J, Antony S, Bohr VA, et al. Von Hippel-Lindau-coupled and transcription-coupled nucleo-tide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res 2008;14:6449-55.
18. Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, Perez L, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7:1309-18.
19. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, Honrado E, Campoverde A, et al. Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 andCUL4A aslikelycandidatetarget genes.BreastCancerRes 2009;11:R86.
20. Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci 2009;34:562-70.
21. Lee J, Zhou P. Cullins and cancer. Genes Cancer 2010;1:690-9.
22. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9. (Pubitemid 34185394)
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, VanRoy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
24. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005;85:154-9. (Pubitemid 40128049)
25. McNeill RE, Miller N, Kerin MJ. Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol 2007;8:107.
26. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.
27. Rasband WS. Image J, Image Processing and Analysis in Java. 2006. Available from: http://imagej.nih.gov/ij/
28. Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding optimal cutpoints for continuous covariants with binary and time-to-event outcomes. 2006. Available from: http://mayoresearch.mayo. edu/mayo/research/ biostat/upload/79.pdf.
29. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999;18:1957-65. (Pubitemid 29150082)
30. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9. (Pubitemid 30212318)
31. Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascon A, et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 2007;20:1298-306. (Pubitemid 350126855)
32. Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007;81:280-7. (Pubitemid 47030571)
33. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000;21: 1761-5.
34. Tapia T, Smalley SV, Kohen P, Munoz A, Solis LM, Corvalan A, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 2008;3: 157-63.
35. Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100:339-48. (Pubitemid 46146084)
36. Kapetanaki MG, Guerrero-Santoro J, Bisi DC, Hsieh CL, Rapic-Otrin V, Levine AS. The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. Proc Natl Acad Sci U S A 2006;103:2588-93.
37. Zhong W, Feng H, Santiago FE, Kipreos ET. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. Nature 2003;423:885-9. (Pubitemid 36781282)
38. Wang H, Zhai L, Xu J, Joo HY, Jackson S, Erdjument-Bromage H, et al. Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell 2006; 22:383-94. (Pubitemid 44308132)
39. Fei J, Kaczmarek N, Luch A, Glas A, Carell T, Naegeli H. Regulation of nucleotide excision repair by UV-DDB: prioritization of damage recognition to internucleosomal DNA. PLoS Biol 2011;9:e1001183.
40. Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics 2010;11:865-78.
41. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
42. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009;4:e6146.
43. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 2006;66:41-5. (Pubitemid 43166006)